Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: ImmunityBio Inc. is conducting a clinical study titled ‘Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID.’ The study aims to assess the safety and effectiveness of Anktiva in treating Long COVID, a condition characterized by persistent symptoms following a COVID-19 infection. This research is significant as it addresses the growing need for effective treatments for Long COVID, which affects a substantial number of individuals post-infection.
Intervention/Treatment: The study is testing Anktiva, a drug administered subcutaneously at a dose of 600 micrograms. Anktiva is designed to treat Long COVID by potentially alleviating the persistent symptoms associated with the condition.
Study Design: This is an interventional Phase 2 study with a single-group assignment. There is no allocation or masking involved, meaning all participants receive the treatment, and the primary purpose is to evaluate the treatment’s effectiveness.
Study Timeline: The study began on July 30, 2025, with the latest update submitted on August 13, 2025. These dates are crucial as they indicate the study is in its early stages, with ongoing recruitment and data collection.
Market Implications: The progress of this study could positively impact ImmunityBio’s stock performance by showcasing their commitment to addressing Long COVID, a pressing global health issue. Success in this trial could enhance investor sentiment and position the company as a leader in innovative COVID-19 treatments, potentially influencing the competitive landscape in the biopharmaceutical industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.